Hormonal Implications in the Development and Treatment of Prostate Cancer

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 2, 2007, Pages 421-434

  Ip, Christopher ^a   Hall, Simon J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; FINASTERIDE; FLUTAMIDE; GLUTAMINE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; BODY FAT DISTRIBUTION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; DIARRHEA; DISEASE PREDISPOSITION; EYE DISEASE; FOLLOW UP; GENE MUTATION; GYNECOMASTIA; HIGH RISK POPULATION; HORMONAL REGULATION; HOT FLUSH; HUMAN; IMPOTENCE; INSULIN RESISTANCE; LETHARGY; LIBIDO DISORDER; LIVER TOXICITY; MASTALGIA; METASTASIS; MONOTHERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANDROGENS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 34249282712     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.03.009     Document Type: Review

References (56)

1. Silver R.I., Wiley E.L., Thigpen A.E., et al. Cell type specific expression of steroid 5 alpha-reductase 2. J Urol 152 2 Pt 1 (1994) 438-442
2. Wilson J.D., and Roehrborn C. Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 84 12 (1999) 4324-4331
3. Meikle A.W., and Stanish W.M. Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 54 6 (1982) 1104-1108
4. Ghanadian R., Puah C.M., and O'Donoghue E.P. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 39 6 (1979) 696-699
5. Hammond G.L., Kontturi M., Vihko P., et al. Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol 9 2 (1978) 113-121
6. Comstock G.W., Gordon G.B., and Hsing A.W. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 2 3 (1993) 219-221
7. Chen C., Weiss N.S., Stanczyk F.Z., et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 12 12 (2003) 1410-1416
8. Stattin P., Lumme S., Tenkanen L., et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108 3 (2004) 418-424
9. Platz E.A., Leitzmann M.F., Rifai N., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14 5 (2005) 1262-1269
10. Barrett-Connor E., Garland C., McPhillips J.B., et al. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 50 1 (1990) 169-173
11. Meikle A.W., Smith J.A., and Stringham J.D. Production, clearance, and metabolism of testosterone in men with prostatic cancer. Prostate 10 1 (1987) 25-31
12. Gann P.H., Hennekens C.H., Ma J., et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 16 (1996) 1118-1126
13. Parsons J.K., Carter H.B., Platz E.A., et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14 9 (2005) 2257-2260
14. Thorpe J.F., Jain S., Marczylo T.H., et al. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 89 3 (2007) 207-211
15. Rhoden E.L., and Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 170 6 Pt 1 (2003) 2348-2351
16. Wang C., Cunningham G., Dobs A., et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89 5 (2004) 2085-2098
17. Rhoden E.L., and Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350 5 (2004) 482-492
18. Edwards A., Hammond H.A., Jin L., et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12 2 (1992) 241-253
19. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22 15 (1994) 3181-3186
20. Irvine R.A., Yu M.C., Ross R.K., et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55 9 (1995) 1937-1940
21. Gilligan T., Manola J., Sartor O., et al. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer 3 2 (2004) 98-103
22. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 3 (2003) 215-224
23. Rubin M.A., Allory Y., Molinie V., et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 66 5 (2005) 930-934
24. Thorpe J.F., Jain S., Marczylo T.H., et al. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 89 3 (2007) 207-211
25. Chu K.C., Tarone R.E., and Freeman H.P. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97 6 (2003) 1507-1516
26. Huggins C., and Hodges C.V. Studies on prostatic cancer. I: the effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293
27. White J.W. The results of double castration in hypertrophy of the prostate. Ann Surg 22 (1895) 1
28. Byar D.P., and Corle D.K. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 7 (1988) 165-170
29. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 311 20 (1984) 1281-1286
30. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 13 (2001) 948-955
31. Smith M.R., Lee H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91 4 (2006) 1305-1308
32. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 27 (2006) 4448-4456
33. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
34. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998) 1036-1042
35. Denis L., and Murphy G.P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72 (1993) 3888-3895
36. Schmitt B., Wilt T.J., Schellhammer P.F., et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57 (2001) 727-732
37. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164 (2000) 1579-1582
38. Boccardo F., Barichello M., Battaglia M., et al., Italian Prostate Cancer Group. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 42 5 (2002) 481-490
39. McLeod D.G., See W.A., Klimberg I., et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 176 (2006) 75-80
40. McLeod D.G., Iversen P., See W.A., et al., Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 2 (2006) 247-254
41. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 79 2 (1997) 235-246
42. Messing E.M., Manola J., Yao J., et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 6 (2006) 472-479
43. Lawton C.A., Winter K., Grignon D., et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 23 4 (2005) 800-807
44. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 12 (2006) 1868-1876
45. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 17 (1999) 1591-1597
46. Soloway M.S., Pareek K., Sharifi R., et al., Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167 1 (2002) 112-116
47. Schulman C.C., Debruyne F.M., Forster G., et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38 6 (2000) 706-713
48. Gleave M.E., Goldenberg L., Chin J.L., et al. Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 169 4 (2003) Abstract 690
49. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 7 (2004) 821-827
50. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 9327 (2002) 103-106
51. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 5 (2001) 1243-1252
52. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 5 (2005) 1285-1290
53. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
54. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
55. Bruchovsky N., Rennie P.S., Coldman A.J., et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50 8 (1990) 2275-2282
56. Bhandari M.S., and Crook J. Hussain. Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol 23 32 (2005) 8212-8218